- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01797432
Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata
December 17, 2020 updated by: University of Minnesota
Safety and Efficacy of Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata
The investigators hypothesize that Restylane® could serve as a repair matrix which also maintains IL triamcinolone acetonide concentrations at higher levels for a longer period of time in the skin, giving a more sustained local anti-inflammatory effect and thus, arresting the AA process and promoting hair regrowth.
Furthermore, the combination of Restylane® with IL triamcinolone acetonide injections may prevent a common side effect, atrophy.
With the prevention of scalp atrophy and the preservation of higher concentrations of triamcinolone acetonide for longer periods of time, patients may see a better clinical response for a longer period of time.
Quality of life may improve as the number of clinic visits decreases as would the number of IL corticosteroid injections.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Department of Dermatology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women ages 18 and greater.
- Alopecia areata diagnosis in the last two years with extensive scalp involvement, between 74% and 99%, alopecia areata must involve the left and right hemispheres of the scalp.
- Willing to abstain from use of over the counter products and prescription products, other than study medications, which may promote hair growth.
- Willing to abstain from the use of non-steroidal anti-inflammatory medications, aspirin, St. Johns Wart, and high doses of Vitamin E supplementation.
- Subjects are capable of giving informed consent.
- Willing to adhere to protocol, including scalp examinations and photography.
Exclusion Criteria:
- Allergy or intolerance to Restylane® or hyaluronate preparations
- Allergy or intolerance to triamcinolone acetonide, 10 mg/cc.
- Underlying disease that might be adversely affected by Restylane® or triamcinolone (ex. patients with bleeding disorders).
- Immunosuppressed patients (history of transplantation, cancer, chemotherapy, splenectomy, HIV).
- Pregnant or lactating female.
- Application of topical immunomodulatory or immunosuppressive agent in the preceding 6 weeks.
- Systemic administration of corticosteroid or other systemic treatment (i.e. prednisone) that has immunomodulatory or other immunosuppressive mechanism of action, in the preceding 8 weeks.
- Clinical evidence of secondary skin infection (i.e., folliculitis).
- Other inflammatory or infectious skin disease that might interfere with evaluations during the study.
- Investigational medications within the past 30 days.
- Patients with susceptibility to keloid formation.
- Severe allergies manifested by a history of anaphylaxis, or history or presence of multiple severe allergies
- Patients with allergies to gram positive bacterial proteins
- Unable to give consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combined IL Kenalog and Restylane
Injection of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on whole scalp and Restylane on half of scalp
|
Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp
Other Names:
Intralesional injections of 2mLs of Restylane on one side of the scalp
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Alopecia Areata Half Head Severity Score (AAHHSS) at 12 Weeks Compared to Baseline
Time Frame: 12 weeks
|
The primary endpoint of evaluating the efficacy of administration of IL triamcinolone acetonide 10 mg/cc and Restylane® in the management of AA is the alopecia areata half head severity score (AAHHSS) comparing week 12 with baseline hair loss.
Four discreet areas of the scalp are examined.
The percent of terminal hair loss in each area is measured by visual estimation.
Those percent figures are multiplied by the total area on one half of the scalp represented by the four respective areas.
1) Left parietal scalp (18% of area), right parietal scalp (18% of area), frontal scalp (40% of area), and occipital scalp (24% of area).
Scores range from 0 to 50, with higher scores indicating more hair loss.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Adverse Events Reported by Subjects
Time Frame: 12 weeks
|
To assess the safety of IL triamcinolone acetonide 10 mg/cc and Restylane® in the management of AA.
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Maria Hordinsky, MD, University of Minnesota - Department of Dermatology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2009
Primary Completion (Actual)
November 1, 2014
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
July 6, 2012
First Submitted That Met QC Criteria
February 20, 2013
First Posted (Estimate)
February 22, 2013
Study Record Updates
Last Update Posted (Actual)
January 12, 2021
Last Update Submitted That Met QC Criteria
December 17, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Pathological Conditions, Anatomical
- Hypotrichosis
- Hair Diseases
- Alopecia
- Alopecia Areata
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Triamcinolone
- Triamcinolone Acetonide
- Triamcinolone hexacetonide
- Triamcinolone diacetate
Other Study ID Numbers
- 0907M69801
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alopecia Areata
-
Services Institute of Medical Sciences, PakistanCompletedExtensive Alopecia AreataPakistan
-
Eli Lilly and CompanyRecruitingSkin Diseases | Pathological Conditions, Anatomical | Alopecia | Hypotrichosis | Hair Diseases | Areata AlopeciaUnited States, Taiwan, Japan, Spain, Korea, Republic of, Germany, France, Mexico, Canada, Poland, Australia, Hungary, Argentina
-
Yale UniversityCompletedAlopecia Areata (AA) | Alopecia Totalis (AT) | Alopecia Universalis (AU)United States
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdActive, not recruitingAlopecia Areata(AA)China
-
University Hospital, RouenCompletedALOPECIA AREATAFrance
-
Inmagene LLCRecruitingAlopecia Areata (AA)United States, Canada
-
University of FloridaWithdrawnFemale Androgenetic AlopeciaUnited States
-
Aclaris Therapeutics, Inc.CompletedAlopecia Totalis (AT) | Alopecia Universalis (AU)United States
-
Throne Biotechnologies Inc.RecruitingAlopecia Areata | Alopecia Totalis | Alopecia UniversalisUnited States
-
Jinnah HospitalCompletedAlopecia Areata | Alopecia Totalis | Alopecia UniversalisPakistan
Clinical Trials on Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)
-
Columbia UniversityUniversity of MinnesotaTerminated
-
Weill Medical College of Cornell UniversityCompletedNail Diseases | Nail PsoriasisUnited States
-
Montefiore Medical CenterTerminatedHidradenitis SuppurativaUnited States
-
University of MinnesotaNational Alopecia Areata FoundationCompletedAlopecia AreataUnited States
-
University of North Carolina, Chapel HillCompletedHidradenitis SuppurativaUnited States
-
NYU Langone HealthWithdrawn
-
University of MichiganTerminatedFemoroacetabular ImpingementUnited States
-
Dubai Health AuthorityUnknownTrigger FingerUnited Arab Emirates
-
Pacira Pharmaceuticals, IncCompletedOsteoarthritis of the KneeUnited States
-
Yuni Eka AnggrainiGadjah Mada UniversityNot yet recruiting